Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 12
Submit an article Journal homepage
487
Views
13
CrossRef citations to date
0
Altmetric
Diabetes: Original Article

Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

Richard M. BergenstalInternational Diabetes Center at Park Nicollet Minneapolis, MN, USACorrespondence[email protected]
,
Louis P. Garrison JrDepartment of Pharmacy, University of Washington Seattle, WA, USA
,
Lesley-Ann MillerEli Lilly and Company Indianapolis, IN, USA
,
Likun HouHealthCore, Inc. Wilmington, DE, USA
,
Amy BlickensderferAmylin Pharmaceuticals, Inc. San Diego, CA, USA
,
Anthony ZagarEli Lilly and Company Indianapolis, IN, USA
,
Shelley StanleyHealthCore, Inc. Wilmington, DE, USA
,
Anuj BhargavaIowa Diabetes and Endocrinology Center, Mercy Medical Center Des Moines, IA, USA
,
Rolin WadeCerner Corporation Kansas City, MO, USA
&
William H. HermanDepartment of Internal Medicine and Epidemiology, University of Michigan Ann Arbor, MI, USA
 show all
Pages 2335-2342 | Accepted 26 Sep 2011, Published online: 16 Nov 2011

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Roberto Anichini, Sabrina Cosimi, Alberto Di Carlo, Paola Orsini, Alessandra De Bellis, Giuseppe Seghieri, Flavia Franconi & Fabio Baccetti. (2013) Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes, Metabolic Syndrome and Obesity 6, pages 123-129.
Read now
Claes-Göran Östenson, Stephan Matthaei, Matthew Reaney, Thure Krarup, Bruno Guerci, Jacek Kiljanski, Carole Salaun-Martin, Hélène Sapin, David Bruhn, Chantal Mathieu & Michael Theodorakis. (2013) Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes, Metabolic Syndrome and Obesity 6, pages 171-185.
Read now

Articles from other publishers (11)

Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark Warren, Signe Harring, Uwe Ziegler & Stephen Bain. (2020) Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk ( SUSTAIN 6) . Diabetes, Obesity and Metabolism 22:8, pages 1339-1347.
Crossref
Liana K. BillingsYehuda HandelsmanMichael HeileDoron SchneiderKathleen Wyne. (2018) Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S30-S41.
Crossref
Shruti Agrawal, Paul Statkevich, Gaurav Bajaj, Yan Feng, Sally Saeger, Dharmesh D. Desai, Jong-Soon Park, Ian M. Waxman, Amit Roy & Manish Gupta. (2017) Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors. The Journal of Clinical Pharmacology 57:3, pages 394-400.
Crossref
Silvia Beatriz Gorban de Lapertosa, Gustavo Frechtel, Elise Hardy & Leobardo Sauque-Reyna. (2016) The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial. Diabetes Research and Clinical Practice 122, pages 38-45.
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Matthew Reaney, Chantal Mathieu, Claes-Göran Östenson, Stephan Matthaei, Thure Krarup, Jacek Kiljański, Carole Salaun-Martin, Hélène Sapin, Michael Theodorakis & Bruno Guerci. (2013) Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health and Quality of Life Outcomes 11:1.
Crossref
Chantal Mathieu, Claes-Göran Östenson, Stephan Matthaei, Matthew Reaney, Thure Krarup, Bruno Guerci, Jacek Kiljański, Carole Salaun-Martin, Hélène Sapin & Michael Theodorakis. (2013) Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. Diabetes Therapy 4:2, pages 285-308.
Crossref
R. M. Bergenstal, Y. Li, T. K. Booker Porter, C. Weaver & J. Han. (2012) Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks . Diabetes, Obesity and Metabolism 15:3, pages 264-271.
Crossref
Gun Woo KimJae Hyun KimMi Young LeeJang Yel ShinYoung Goo ShinEun Ho HaChoon Hee Chung. (2013) Factors Influencing Glycemic Control Response of Sitagliptin. The Journal of Korean Diabetes 14:4, pages 206.
Crossref
Klaus Bielefeldt. (2012) Gastroparesis: Concepts, Controversies, and Challenges. Scientifica 2012, pages 1-19.
Crossref
Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Yury Ivanovich Suntsov, Roza Imailovna Yagudina, Ivan Sergeevich Krysanov, Andrey Yur'evich Kulikov & Evgenia Evgen'evna Arinina. (2010) Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents. Diabetes mellitus 13:1, pages 101-110.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.